SPOREs
Ovarian
Awards
Career Development Awards
Sandra Orsulic
Career Development Award (2005)
Advanced ovarian cancers typically show numerous genetic alterations and chromosomal abnormalities
Daniela Dinulescu
Career Development Award (8/28/2006-7/31/2008)
Therapeutic strategies targeting PI3K pathway in human ovarian cancer
Ronny Drapkin
Career Development Award (8/28/2006-7/31/2008)
HE4 and WAP gene function in ovarian pathogenesis
Developmental Awards
Grant Year 2009
Bo Rueda and Jeffrey Settleman
Defining the sensitivity of parent and hierarchical subpopulations of short term cultured ovarian cancer cells to anti-cancer agents
Shu-Wing Ng and Ross S. Berkowitz
Targeting microRNA in ovarian cancer
Grant Year 2008
Dimitrios Spentzos
The Nrf2/Keap1 pathway as mediator of platinum resistance in ovarian cancer
John Quackenbush
Molecular fingerprints of ovarian cancer and mechanisms of drug resistance
Qing Sheng
Systematic search for and validation of therapeutic targets in human ovarian carcinoma
Samuel Mok
Stromal tumor microenvironment in ovarian cancer pathogenesis
Grant Year 2007
Tan Ince
Analysis of genotype and cell-of-origin effect on ovarian adenocarcinoma phenotype
Patricia Donahoe
Stem cell expression profiles in ovarian cancer
Sandra Orsulic
Oncogenic roles of HOXB13 and its downstream effectors in ovarian cancer
Alex Ng
Serum autoantibody biomarkers for ovarian cancer
Grant Year 2006
Rosemary Foster
Identification and characterization of the ovarian cancer stem cell
Raina Fichorova
Talc and ovarian cancer
Patricia Donahoe
Response markers to select patients for treatment with Müllerian inhibiting substance
Daniel Cramer
Susceptibility to late stage serous ovarian cancer assessed by genome-wide SNP screening
Grant Year 2005
Alex Ng
Targeted therapeutic development using small molecule microarray
Zhenfeng Duan
Preclinical model to validate the Il-6 Stat 3 pathway as a multidrug resistance target in ovarian cancer
Towia Libermann
New approaches for ovarian cancer combination therapy
Richard Penson
Development of a molecular imaging program in ovarian cancer
